CNTA Insider Trading

Insider Ownership Percentage: 7.09%
Insider Buying (Last 12 Months): $5,866,686.94
Insider Selling (Last 12 Months): $17,749,735.94

Centessa Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Centessa Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3-$5M$0$5MTotal Insider BuyingTotal Insider Selling

Centessa Pharmaceuticals Share Price & Price History

Current Price: $14.43
Price Change: Price Decrease of -0.22 (-1.50%)
As of 07/11/2025 05:00 PM ET

This chart shows the closing price history over time for CNTA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
AugSepOctNovDecJanFebMarAprMayJunJul$14.43Closing price on 07/12/25:

SEC Filings (Institutional Ownership Changes) for Centessa Pharmaceuticals (NASDAQ:CNTA)

82.01% of Centessa Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CNTA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$77Mbought$54MsoldQ3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$100M$0$100MTotal InflowsTotal Outflows
Centessa Pharmaceuticals logo
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Read More on Centessa Pharmaceuticals

Today's Range

Now: $14.43
Low: $14.17
High: $14.73

50 Day Range

MA: $12.94
Low: $11.86
High: $14.65

52 Week Range

Now: $14.43
Low: $9.00
High: $19.09

Volume

460,489 shs

Average Volume

756,923 shs

Market Capitalization

$1.93 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.45

Who are the company insiders with the largest holdings of Centessa Pharmaceuticals?

Centessa Pharmaceuticals' top insider shareholders include:
  1. Saurabh Saha (CEO)
  2. Arjun Goyal (Director)
  3. Gregory M Weinhoff (Insider)
  4. David M Chao (Insider)
  5. Mario Alberto Accardi (Insider)
  6. Tia L Bush (CTO)
  7. Iqbal J Hussain (General Counsel)
  8. Karen M Anderson (Insider)
  9. Harris Rotman (SVP)
Learn More about top insider investors at Centessa Pharmaceuticals.